Kornimate/medical-research-clean huggingface dataset:
lidocaine and neuromonitoring in thyroid surgery

Conditions: Thyroid Neoplasm; Parathyroid Neoplasms; Anesthesia

Summary: the aim of this study is to test the hypothesis that the quality of recovery with topical lidocaine is better than placebo.

the use of neuromonitoring in thyroid surgery imposes a number of special demands for anaesthetic management. such demands include avoiding muscle relaxation and local anaesthesia. maintaining a balance between the risk of awakening during surgery and excessively deep anaesthesia in fast track surgery is an important task for the anaesthesiologist. mild anaesthesia in the absence of muscle relaxation increases the risk of developing laryngeal reflexes, coughing during surgery, while excessively deep anaesthesia slows down recovery after surgery and increases the risk of arterial hypotension. the frequency and duration of arterial hypotension, as well as the depth of anesthesia assessed by the bispectral index, are independent risk factors for postoperative cardiovascular complications and long-term mortality. on the other hand, coughing in response to irritation of the endotracheal tube during recovery from anesthesia is recognized as a risk factor for respiratory and cardiovascular complications, as well as postoperative wound insufficiency. optimization the anesthesia by intravenous infusion of lidocaine can improve anesthesia controllability, hemodynamic stability and overall anesthesia recovery rates. local use of lidocaine, including filling the endotracheal tube cuff with its alkalinized solution, has also been shown to be effective in reducing the frequency of laryngeal reflexes upon awakening after surgery of varying duration. however, the efficacy and safety of local use of lidocaine under neuromonitoring conditions has not been studied. despite recommendations to avoid the local use of lidocaine for tracheal intubation, there is evidence of the safety of this technique in the absence of a negative impact on the quality of neuromonitoring. the purpose of this study is to test the hypothesis that the quality of recovery with topical lidocaine is better than placebo. at the same time, the investigators assume that recovery after surgery will be comparable with both local and intravenous use. intergroup differences in arterial hypotension, depth of anesthesia and intraoperative neuromonitoring parameters will also be investigated.

Eligibility criteria:
inclusion criteria: * planned thyroid surgery * age\> 45 years * signed informed consent to participate in the study exclusion criteria: * emergency surgery * redo surgery * contraindications for lidocaine use * pregnancy * enrolment to another randomised clinical trial within the last 30 days
clinical study to investigate psorax35 supplementation in patients with psoriasis

Conditions: Psoriasis Vulgaris

Summary: the main objective of this study is to establish the efficacy and safety of psorax35 supplementation in patients with mild to moderate psoriasis.

psoriasis is a common, genetically predisposed, inflammatory and proliferative disease of the skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red scaly plaques, particularly on extensor parts of limbs and in the scalp. psoriasis can be divided into mild, moderate or severe psoriasis based on the extent of the skin changes psorax35, which is extracted from herring roe are shown to improve the condition of people with psoriasis. the objective of this study is to investigate the effect, safety, and mechanism of action of psorax35 on mild to moderate psoriasis and comorbidities associated with psoriasis through a 32-weeks study. the participants will be randomized into one of two arms; psorax35 and placebo. the study will include a total of 6 treatment visits involving blood samples, photo documentation, psoriasis and severity index (pasi), body surface area (bsa), physician's static global assessment (psga), life quality index (eq-5d, vas and dlqi), blood pressure, blood rate, body mass index (bmi), waist circumference, waist/hip ratio, and 24 hrs dietary recall. at visit 4 blood samples, blood pressure, blood rate, bmi, waist circumference, waist/hip ratio, and 24 hrs dietary recall are not included.

Eligibility criteria:
inclusion criteria: 1. female and male subjects at least 18 years old understanding norwegian oral and written information 2. diagnosis of mild to moderate psoriasis vulgaris for at least 6 months prior to mild to moderate psoriasis vulgaris as defined at screening by: * pasi scores less than 10 (mild psoriasis) and * body surface area affected by chronic plaque psoriasis 1%-9.9% (mild and moderate psoriasis) 3. women of childbearing potential must have a negative serum pregnancy test at the screening visit. exclusion criteria: 1. pregnancy 2. initiation of a drug known to cause or exacerbate psoriasis 3. having received an investigational medical product (imp) or investigational device within 28 days' prior randomization 4. alcohol and drug abuse or any condition associated with poor compliance 5. malabsorption disorder 6. scheduled hospitalization during the course of the study that could compromise the study 7. major diseases or infections 8. known or suspected sensitivity or allergic reactions to the imp or excipients 9. presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk 10. planned trip abroad to a sunny resort involving active sun exposure 11. any anti psoriatic treatment 12. immunosuppressive - immunomodulating treatment given for any other reason than psoriasis 13. uv treatment and return from a sunny resort involving active sun exposure for the last 4-6 weeks

Keywords: chronic plaque psoriasis inflammation cardiovascular diseases
validation of the ich score for the prediction of 12-month functional outcome in patients with primary intracerebral hemorrhage

Conditions: Intra Cerebral Hemorrhage

Summary: the goal of this observational study is to analyze the validity of the intracerebral hemorrhage (ich) score and a new modified ich score for the prediction of 12-month functional outcome in patients with primary ich. participants who were admitted to ntuh rehabilitation ward will be followed up to 12 months after the onset of ich. the follow-up will be conducted by phone interviews.

the ich score had been utilized to predict the 30-day mortality after acute intracerebral hemorrhage (ich), but there's still no reliable tool in predicting the long-term functional outcome in ich patients. recently, there have been some studies that use ich score to predict the prognosis of functional outcome in ich patients. however, most studies included patients in western societies. relevant studies in taiwan were scarce. the present study will follow up the patients with ich, who were admitted to ntuh rehabilitation ward, up to 12 months post stroke. the follow-up will be conducted by phone interviews at certain time after the onset of ich. investigators aim to analyze the validity of the ich score for the prediction of 12-month functional outcome in patients with primary ich. investigators will also add other variables to see if the revised score could better predict the prognosis among ich patients.

Eligibility criteria:
inclusion criteria: * aged 20 years or older * had been admitted to a neurology, neurosurgery, or rehabilitation ward with a diagnosis of primary intracerebral hemorrhage (ich) * had a diagnosis of ich confirmed by a brain computed tomography (ct) * have written informed consent given by themselves or by their legal representative exclusion criteria: * ich related to aneurysm, arteriovenous malformation, or trauma * died before discharge

Keywords: intracerebral hemorrhage functional outcome prognosis survivors rehabilitation
the predictors for asthma control by stepwise treatment during 6 months in korean elderly

Conditions: Asthma

Summary: the predictors for asthma control by stepwise treatment during 6 months in korean elderly


Eligibility criteria:
inclusion criteria: * patients aged 60 years or more, articulate in korean * patients diagnosed with asthma, at least 1 year in duration. exclusion criteria: * patients being followed-up for asthma treatment less than 1 year before baseline * patients taking immune therapy * patients previously enrolled/randomized in the present clinical trial

Keywords: predictors for asthma control asthma exacerbation rate mean frequency of pft sputum assessments refill adherence(%) prescription persistence
preliminary study on the metastatic rate and clinical significance of the anterior leaf of vesicouterine ligament in early stage cervical cancer

Conditions: Cervical Cancer

Summary: the purpose of this study is to preliminarily explore the metastatic rate and clinical significance of the anterior leaf of vesicouterine ligament resection for early stage cervical cancer, so as to further improve the postoperative quality of life of patients and reduce the incidence of postoperative urinary complications.

the patients with cervical cancer who underwent abdominal radical hysterectomy（type c）plus pelvic lymph node dissection by the same surgical team at the department of gynecological oncology, sun yat-sen memorial hospital, sun yat-sen university, were included. according to the resection range of the anterior leaf of vesicouterine ligament (vul), patients were divided into type c resection group (near the bladder wall) and b type resection group (above the ureter). the anterior leaf of the vul in the type c resection group was sent to pathological biopsy separately, and the metastasis rate was further clarified by the pathological "ultrastaging" method. by comparing the clinicopathological characteristics of patients with metastasis and non-metastasis, the potential risk factors of vul metastasis were analyzed. the oncological outcomes of patients with different resection range of the anterior vul were compared. at the same time, the functional assessment of cancer therapy-cervical（fact-cx）cervical cancer patient quality of life score table was used to evaluate cervical cancer patients after surgery. the relevant factors that may affect the quality of life score are included in the multiple linear regression analysis to obtain independent risk factors that affect the quality of life of the patient after surgery.

Eligibility criteria:
inclusion criteria: 1. histological confirmation of squamous, adenocarcinoma, or adenosquamous cervical carcinoma (even neuroendocrine or clear cell carcinoma) 2. radiographically confirmed tumor limited to the cervix or upper third vagina, but without evidence of lymph node metastasis 3. stage ia2-iia2 ( figo 2018) 4. treated initially or just underwent cervical conization before 5. underwent the abdominal type c (q-m classification) radical hysterectomy with pelvic lymph node dissection by the same team 6. underwent the bilateral type c al-vul resection during the surgery 7. the eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: 1. not stage ia2-iia2 ( figo 2018) 2. history of abdominal or pelvic radiotherapy 3. evidence of metastatic disease detected by pect, mri or ct 4. the surgeon evaluated the patient as unsuitable for abdominal radical hysterectomy or the patient as refusing abdominal surgery 5. patients with other mailgnant tumors except cervical cancer 6. incompetence of the clinical, surgical and pathological data

Keywords: cervical cancer radical hysterectomy ultrastaging vesicouterine ligament
tgfb1 and lama1 gene polymorphisms in high myopia

Conditions: High Myopia; Gene Mutations

Summary: the investigators aimed to investigate tgfb1 and lama1 gene polymorphisms in children with high myopia in order to determine the genetic basis of large myopic shifts causing severe visual impairment and complications. seventy-four children with high myopia (≥6 diopters \[d\]; study group) and 77 emmetropic children (±0.5d; control group) were included. genetic and polymorphism analyses were performed in the medical genetics laboratory using dna purified from the patients' blood samples.


Eligibility criteria:
inclusion criteria: * patients under the age of 13 * patients with cycloplegic refraction values ≥6 d (for study group) * emmetropic patients (for control group) exclusion criteria: * patients who had additional ocular pathology that may affect refraction (such as glaucoma, cataracts, corneal disease) * patients with history of ocular surgery

Keywords: high myopia tgfb1gene polymorphisms lama1 gene polymorphisms
frailty phenotype assessments to optimize treatment strategies for older patients with hematologic malignancies

Conditions: Leukemia, Acute; MDS

Summary: the purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, car t-cell therapy, or allogeneic stem cell transplant.


Eligibility criteria:
eligibility criteria arm a: * age 60 years or older. * new diagnosis of acute leukemia or mds, or suspected diagnosis. * able to consent to the study. eligibility criteria arm b: * age 60 years or older with a hematologic malignancy. * plan to undergo an allogeneic blood or marrow transplantation or car t-cell therapy. * able to consent to the study.
taltz in combination with enstilar for psoriasis

Conditions: Psoriasis

Summary: enstilar in combination with taltz for plaque psoriasis.

a single center study of 25 subjects to assess the addition of enstilar foam in patients receiving taltz for ≥ 24 weeks with bsa between 3% and 8%.

Eligibility criteria:
inclusion criteria: * male or female adult ≥ 18 years of age; * diagnosis of chronic plaque-type * body surface area between 3%-8%. * patient has been treated with taltz for a minimum of 24 weeks * females of childbearing potential (fcbp) must have a negative pregnancy test at screening and baseline. fcbp who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (iud); tubal ligation; or partner's vasectomy; male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. * subject must be in general good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination * able and willing to give written informed consent prior to performance of any study-related procedures. exclusion criteria -˂3% or \>8% bsa * patient not receiving taltz, or receiving taltz \<24 weeks * any condition, which would place the subject at unacceptable risk if he/she were to participate in the study. * pregnant or breast feeding, or considering becoming pregnant during the study. * use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer). * use of oral systemic medications for the treatment of psoriasis within 4 weeks. * patient used other topical therapies to treat within 2 weeks of the baseline visit. * patient received uvb phototherapy within 2 weeks of baseline. * patient received puva phototherapy within 4 weeks of baseline. * patient has a known hypersensitivity to the excipients of enstilar® as stated in the label.
effects of losartan on insulin resistance in patients with heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the effects of losartan, an arb, on glucose metabolism and inflammatory cytokines in chf patients treated with ace inhibitors.

chronic heart failure (chf) is associated with marked insulin resistance, characterized by both fasting and stimulated hyperinsulinemia. furthermore, insulin resistance is a predictor of chf and associated with more severe disease and a worse prognosis in patients with chf. in chf patients, therefore, insulin resistance is not merely a function of adiposity and may have implications in the pathophysiology of chf disease progression. angiotensin ii negatively modulates insulin-mediated actions by regulating multiple levels of the insulin signaling cascade such as the insulin receptor, irs, and pi3-kinase. furthermore, both ace inhibitors and angiotensin ii receptor blockers (arb) improve glycemic status not only in patients with type ii diabetes but also in patients with hypertension and the metabolic syndrome. on the other hand, it is well known that some cytokines, such as tnf-α, are involved with pathophysiology of insulin resistance and chf. however, it is still unclear whether the arb improves insulin resistance in chf patients already treated with ace inhibitors and whether there is the relationship between insulin resistance and inflammatory cytokines in chf patients already treated with ace inhibitors. therefore, the purpose of this study is to evaluate the effects of losartan, an arb, on glucose metabolism and inflammatory cytokines in chf patients treated with ace inhibitors.

Eligibility criteria:
inclusion criteria: * chronic stable heart failure exclusion criteria: * renal dysfunction or under treatment with antidiabetic agents

Keywords: heart failure insulin resistance losartan ace inhibitor inflammatory cytokine
artdeco study: a study of ro4995819 in patients with major depressive disorder and inadequate response to ongoing antidepressant treatment

Conditions: Major Depressive Disorder

Summary: this multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of ro4995819 as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. patients will be randomized to receive once daily doses of 5 mg, 15 or 30 mg of ro4995819 or matching placebo. the anticipated time on study treatment is 6 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, 18-65 years of age * major depression disorder without psychotic features * inadequate response to current, ongoing antidepressant treatment as defined by protocol * having at least one but no more than 2 antidepressant treatment trial failures * body mass index (bmi) 18.0-35.0 kg/m2 inclusive exclusion criteria: * patient currently receives treatment with a combination of 3 or more antidepressants * significant ongoing use of high doses of barbiturates, benzodiazepines or other anxiolytic drugs * patient previously received ro4995819 * patient participated in an investigational drug or device trial within 6 months of screening * history of non-response to, or current use of non-pharmacological treatment including electroconvulsive therapy (ect), vagus nerve stimulation (vns), or repetitive transcranial magnetic stimulation (rtms) * past or present psychotic symptoms
does patent foramen ovale size matter in men and women

Conditions: Patent Foramen Ovale

Summary: a patent foramen ovale (pfo) is present in \~30% of the general population. the pfo has historically been considered to be trivial. however, recent work by the investigator's group and others has identified that, compared to individuals without a pfo, those with a pfo have worse pulmonary gas exchange efficiency, have a higher core body temperature, blunted ventilatory responses to chronic hypoxia and acute carbon dioxide and increased susceptibility to altitude illnesses such as acute mountain sickness, and high altitude pulmonary edema (lovering, elliott \& davis j appl physiol 2016). specific to this application,subjects with a pfo may have worse pulmonary gas exchange efficiency because a pfo is a potential source of right-to-left shunt that will make pulmonary gas exchange efficiency worse. if true, then this may negatively impact exercise capacity and/or exercise tolerance. further, in those with a pfo compared to those without, preliminary work from the investigator's lab indicates that there may be an effect of pfo size on pulmonary gas exchange efficiency. this is such that those with a large pfo (grade 3 or higher) display significantly worse gas exchange efficiency compared to those with a small (grade 2 or lower) or no pfo,even at low exercise workloads. additionally, the investigators were curious as to whether there would be a sex effect, but due to logistical constraints, the investigators were unable to recruit an equal number of female and male subjects. thus, in addition to the potential size effect on the investigators outcome measures, the investigators would like to build on this work by examining the potential effect of biological sex. although a pfo has been traditionally considered to have a minimal impact of physiology and pathophysiology, emerging evidence suggests this may not be the case. the investigator's lab is focused on understanding how and why a relatively small hole in the heart (pfo) can have a relatively large impact on cardiopulmonary and respiratory physiology, and how these impacts may be based on the size of the pfo.


Eligibility criteria:
inclusion criteria: * men and women aged 18-40 * known to have/not have a pfo. exclusion criteria: * previous history of coronary artery disease(ischemic heart disease such as angina, heart attack, myocardial infarction). * failure of modified allen's test in both hands. * currently taking medications or herbal supplements for any heart or respiratory disease that they cannot stop taking for 48 hrsprior to testing (seasonal allergy medication not included in exclusion medications). * lidocaine, nitroglycerine or heparin allergy. * women who are pregnant or trying to become pregnant. * previous history of any condition that would prevent the subject from performing cycle ergometer exercise (for exercise study only).
etoricoxib versus ibuprofen in third molar extraction pain

Conditions: Dental Extraction

Summary: the aim of this study is to evaluate the analgesic efficacy of etoricoxib compared with a well known and widely used non-steroid antinflammatory drug, ibuprofen, in third molar extraction pain. at this time, there are no data about the efficacy of etoricoxib for reducing pain following dental extraction. this will be a single center, randomized, double-blind study, in which patients with moderate to severe pain following third molar extraction will be randomized to receive etoricoxib (120 mg in a single dose + 2 dose of placebo pro day for 3 days) or ibuprofen (1800 mg in 3 doses pro day for 3 days). paracetamol plus codeine will be used as rescue medication. pain assessment will be performed using a 11-point pain intensity scale (0 = no pain and 10 = worster pain) during the first 3 days after dental extraction. patients will be enrolled 15 days before the dental extraction. during enrollment visit a complete clinical evaluation with particular attention for potential exclusion criteria (e.g. hypertension and cardiovascular risk factors) as well as blood analyses will be performed. a follow-up visit will be performed 15 days after the dental extraction. tolerability will be assessed through recording of adverse events.


Eligibility criteria:
inclusion criteria: * subjects with age \> 18 years * in good health status (assessed in occasion of enrollment visit) without any major systemic illness * candidate to third molar extraction and presenting local pain within 2 hours after dental extraction exclusion criteria: * patients with any major systemic illness * patients with a clinical history of drug abuse * patients with hypertension and/or a condition of increased cardiovascular risk * pregnant or lactating women * patients with a history of hypersensitivity/allergy to analgesic drugs, including classical nsaid or coxibs * patients with either high levels of liver enzymes (major of 1.5x the upper limit of reference interval) or of creatinine(major of 1.2x the upper limit of reference interval) * patients with either a history of peptic ulcer or of haemorrhagic diathesis * patients who can not ensure an adequate compliance for the study

Keywords: third molar extraction etoricoxib ibuprofen analgesic efficacy pain